Tweet
Abstract ?
Hum Vaccin. 2010 Nov 1;6(11):12-17. [Epub ahead of print]
Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.
Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, Li P, Gillard P, Roman F.
Hara-doi Hospital, 6-40-8, Aoba, Higashi-ku, Fukuoka Japan.
Abstract
We are grateful to the New York Medical College, New York for providing the vaccine virus strain and to the National Institute for Biological Standards and Control (NIBSC, UK) and the Therapeutic Goods Administration (TGA) from the Australian Government for providing the reference standards. The authors are indebted to the participating study volunteers, clinicians, nurses and laboratory technicians at the study sites as well as to the sponsor's project staff for their support and contributions throughout the study. We are grateful to all teams of GSK Biologicals for their contribution to this study, especially Kazunori Yagi, Maki Matsuzaki, Kayoko Endo, Kenji Ishizuka, Shinobu Tamura, Hiroshi Tamura for clinical study management and site monitoring, Karl Walravens and Roger Bernhard from the clinical and serological laboratory teams, Liliana Manciu for preparation of the study protocol and related study documentation, Koen Ceulemans for global study management, Dorothy Slavin (Clinical Safety Representative), Edith L?pine for project management, and David Vaughn for project direction. The authors thank Avishek Pal (GlaxoSmithKline Biologicals) for medical writing and Dr Antoine Minne (Keyrus Biopharma) and Dr. Wendy Van Doorslaer (XPE Pharma & Science) for editorial assistance and manuscript coordination.
PMID: 20980795 [PubMed - as supplied by publisher]
Hum Vaccin. 2010 Nov 1;6(11):12-17. [Epub ahead of print]
Immunogenicity and safety of a novel AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.
Ikematsu H, Nagai H, Kawashima M, Kawakami Y, Tenjinbaru K, Maeda A, Li P, Gillard P, Roman F.
Hara-doi Hospital, 6-40-8, Aoba, Higashi-ku, Fukuoka Japan.
Abstract
We are grateful to the New York Medical College, New York for providing the vaccine virus strain and to the National Institute for Biological Standards and Control (NIBSC, UK) and the Therapeutic Goods Administration (TGA) from the Australian Government for providing the reference standards. The authors are indebted to the participating study volunteers, clinicians, nurses and laboratory technicians at the study sites as well as to the sponsor's project staff for their support and contributions throughout the study. We are grateful to all teams of GSK Biologicals for their contribution to this study, especially Kazunori Yagi, Maki Matsuzaki, Kayoko Endo, Kenji Ishizuka, Shinobu Tamura, Hiroshi Tamura for clinical study management and site monitoring, Karl Walravens and Roger Bernhard from the clinical and serological laboratory teams, Liliana Manciu for preparation of the study protocol and related study documentation, Koen Ceulemans for global study management, Dorothy Slavin (Clinical Safety Representative), Edith L?pine for project management, and David Vaughn for project direction. The authors thank Avishek Pal (GlaxoSmithKline Biologicals) for medical writing and Dr Antoine Minne (Keyrus Biopharma) and Dr. Wendy Van Doorslaer (XPE Pharma & Science) for editorial assistance and manuscript coordination.
PMID: 20980795 [PubMed - as supplied by publisher]
